金河生物：控股股东金河控股累计质押公司股份8532万股

Group 1 - The core point of the article is that Jinhe Biological has announced the pledge of shares by its controlling shareholder, Jinhe Holdings, which does not pose any risk to the company's operations or governance [1] - As of the announcement date, Jinhe Holdings has pledged a total of 85.32 million shares, accounting for 38.92% of its holdings, while the total pledged shares by Jinhe Holdings and its concerted parties account for 33.3% of their holdings [1] - Jinhe Biological's revenue composition for the first half of 2025 is as follows: veterinary chemical drugs 61.83%, agricultural product processing 19.76%, veterinary biological products 11.12%, environmental protection business 4.97%, and others 2.15% [1] Group 2 - The current market capitalization of Jinhe Biological is 5.2 billion yuan [1] - The article also highlights the broader context of the biopharmaceutical market in China, noting that this year, overseas licensing has generated $80 billion [1]